hit tracker

COVID-19 and Type 2 diabetes: regional experts shed light on the latest scientific updates and clinical practices in illness monitoring for patient learning

COVID-19 and Type 2 diabetes: regional experts shed light on the latest scientific updates and clinical practices in illness monitoring for patient learning

Boehringer Ingelheim - one of the top pharmaceutical firms - held a regional media webinar titled ‘Managing Type 2 Diabetes during COVID-19' with the involvement of leading medical care specialists that gave the latest updates on Type 2 diabetes (T2D) administration throughout the pandemic. The local media event formed part of the 'Regional Interchange on Diabeties' (e-RID) internationally-accredited digital program, arranged by Boehringer Ingelheim, targeting more than 5,000 worldwide and local medical care experts in the Middle East, Turkey and Africa region. By hosting popular experts from the U.S.A., Canada as well as the UK, the clinical program focuses on exchanging experiences as well as techniques in handling Type 2 diabetes and its issues throughout COVID-19.

Thirty-nine million individuals are presently dealing with diabetes in the Middle East and North Africa region, and it is also estimated that by 2045, around 82 million individuals will have the illness, according to the International Diabetic Issues Federation. With diabetic issues being reported as a danger variable for the intensity of COVID-19, people with the condition are advised to take safety measures to avoid infection, safety measures such as cleaning hands thoroughly, cleaning and decontaminating objects and surfaces that are touched often, as well as preventing contact with any person showing signs and symptoms of respiratory illness, such as coughing. People dealing with T2D must pay additional focus to their glucose levels and check them consistently to prevent issues caused by high or reduced blood glucose levels. If they display flu-like symptoms, it is important that they seek advice from a physician quickly for clinical support .

"At a time where the world is focused on COVID-19, it is crucial to highlight the diseases affecting the lives of so many patients in our region such as Type 2 Diabetes. We felt committed to providing patients living with T2D, their caregivers and the wider healthcare community credible sources of information related to diabetes management and necessary precautions during the pandemic," stated Mohammed Al-Tawil, Regional Managing Director and Head of Human Pharma at Boehringer Ingelheim.

" People with diabetic issues as well as related comorbidities are at a greater threat of issues from COVID-19. 40 percent of COVID-19 death cases in the UAE and also Kuwait had diabetes. It is therefore critical that we enlighten people on diabetic issues, self-management and also comorbidities currently," clarified Dr. Mohammed Hassanein, Senior consutant in Endocrinology as well as Diabetes at Dubai Hospital. "People dealing with unrestrained T2D face a greater danger of acquiring the infection than individuals dealing with regulated T2D. Our concern is consequently to make certain reliable type 2 diabetes control at this vital time."

During the event, Dr Paola Atallah, Specialist Endocrinologist at Saint George Medical Facility University Medical Center in Lebanon, focused on ideas and support for people intending to go back to their jobs during COVID-19. "Tension levels as well as disturbances to diet plan as well as exercise throughout COVID-19 can contribute to worsening outcomes for people with T2D. It is for that reason, necessary that patients consistently follow up with their physicians virtually, keep a healthy diet plan and health and fitness regimen, stock up on clinical supplies, and also have an emergency contact on speed dial in case of frightful circumstances", she described.

Dr. Atallah additionally encouraged individuals dealing with diabetes throughout the area to proceed working from another location as well as to try to decrease contact with those outside their homes: "If people absolutely have to go back to function, I advise them to make certain they follow stringent social distancing procedures, wash their hands often, as well as stay clear of touching their faces."

Cardiovascular disease (CVD) continues to be the number one killer of individuals with type 2 diabetes, making up around 52% of type 2 diabetic patients around the world. Diabetic issues are a well-known risk element for CVD, so are conditions such as high blood pressure as well as excessive weight, all generally seen in individuals with diabetic issues. Collectively, this implies that the threat of death because of CVD up 4 times higher in individuals diagnosed with T2D [7]

Reducing cardiovascular risk is an important part of diabetic issues management, for that reason people are encouraged to enlighten themselves on exactly how to alter cardio risk factors in order to gain the very best CVD end results. A patient-centric as well as all natural approach is required to guide the choice of pharmacologic agents used in people with T2D because of the persistent nature of the disease. Considerations include efficacy, hypoglycemia risk, history of CVD, impact on weight, potential side effects, renal effects, delivery method, cost, and patient preferences

The " Managing type 2 diabetes during COVID-19" webinar session was supplied by leading endocrinologists from the Middle East; Professor Dr Yehia Ghanem, Professor of Diabetes, Lipid and Metabolism, as well member of the Egyptian Diabetes National Committee, Dr. Eman Sheshah, Director of Endocrine as well as Diabetes Center in King Salman Health Center Riyadh in KSA and also Dr. Thamer Alessa, Endocrinologist and Head of Endocrinology, Diabetes and also Metabolic Division at Jaber Al-Ahmad Health Center, Kuwait., In April 2020, Boehringer Ingelheim released its Worldwide Assistance Program to step up its efforts on behalf of the battle against COVID-19. The programme focuses on four areas: economic and in-kind donations for local emergency condition help worth 7 million euros, research for COVID-19 therapies via a team of over 100 extremely dedicated scientists from all from all areas of research and development, volunteering to bring COVID-19 alleviation and also sustaining social business owners through the "Making More Wellness" relief fund.

"Our agencies in the Middle East, Turkey and also Africa have signed up to bring financial relief, safety materials and donations of medicine to health care organizations and communities in need. Currently, we have arranged funds and offered in-kind contributions for neighborhood emergency situation aid in Jordan, Turkey, Morocco and Tunisia. We are presently getting ready to provide similar assistance in other countries, such as of Lebanon, Egypt and Algeria, where it is also required," Tawil added.